Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats

Seizure

Volumn 19, Issue 5, 2010, Pages 296-299

  Coppola, Giangennaro ^a   Arcieri, Salvatore ^a   D'Aniello, Alfredo ^a   Messana, Tullio ^a   Verrotti, Alberto ^b   Signoriello, Giuseppe ^a   Pascotto, Antonio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Levetiracetam; Rats; Seizure threshold; Subcutaneous pentylenetetrazol; Valproic acid

Indexed keywords

ETIRACETAM; PENTETRAZOLE; VALPROIC ACID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; LATENT PERIOD; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SEIZURE THRESHOLD; WISTAR RAT;

ANIMALS; ANTICONVULSANTS; CONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; EPILEPSY, GENERALIZED; EPILEPSY, TONIC-CLONIC; INJECTIONS, SUBCUTANEOUS; MALE; PENTYLENETETRAZOLE; PIRACETAM; RATS; RATS, WISTAR; SEIZURES; VALPROIC ACID;

EID: 77952582413     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2010.03.004     Document Type: Article

References (20)

1. Coppola G., Mangano S., Tortorella G., Pelliccia A., Fels A., Romano A., et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res 59 (2004) 35-42
2. Di Bonaventura C., Fattouch J., Mari F., Egeo G., Vaudano A.E., Prencipe M., et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 7 (2005) 231-235
3. Striano P., Coppola A., Pezzella M., Ciampa C., Specchio N., Ragona F., et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 17 (2007) 250-254
4. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann-Delgado J., and N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 70 (2008) 607-616
5. Verrotti A., Cerminara C., Domizio S., Mohn A., Franzoni E., Coppola G., et al. Levetiracetam in absence epilepsy. Dev Med Child Neurol 50 (2008) 850-853
6. Gower A.J., Noyer M., Verloes R., Gobert J., and Wülfert E. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 222 (1992) 193-203
7. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22 (1995) 207-213
8. Löscher W., and Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232 (1993) 147-158
9. Löscher W., Hönack D., Fassbender C.P., and Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8 (1991) 171-189
10. Woodbury L.A., and Davenport V.D. Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn Ther 1 (1952) 97-107
11. Swinyard E.A. Laboratory evaluation of antiepileptic drugs. Review of laboratory methods. Epilepsia 10 (1969) 107-119
12. Thavendiranathan P., Chow C., Cunnane S., and McIntyre Burnham W. The effect of the 'classic' ketogenic diet on animal seizure models. Brain Res 959 (2003) 206-213
13. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 42 Suppl 4 (2001) 13-18
14. Krall R.L., Penry J.K., White B.G., Kupferberg H.J., and Swinyard E.A. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 19 (1978) 409-428
15. Bailleux V., Vallée L., Nuyts J.P., Hamoir G., Poupaert J.H., Stables J.P., et al. Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl) phthalimide and prototype antiepileptic drugs in mice and rats. Epilepsia 36 (1995) 559-565
16. Doheny H.C., Ratnaraj N., Whittington M.A., Jefferys J.G., and Patsalos P.N. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 34 (1999) 161-168
17. Löscher W., and Fiedler M. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VI. Seasonal influences on maximal electroshock and pentylenetetrazol seizure thresholds. Epilepsy Res 25 (1996) 3-10
18. Klitgaard H., Matagne A., Gobert J., and Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353 (1998) 191-206
19. Likhodii S.S., Musa K., Mendonca A., Dell C., Burnham W.M., and Cunnane S.C. Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia 41 (2000) 1400-1410
20. Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 8 (2006) 113-129